Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.

by Emilia Quattrocchi, Mikkel Østergaard, Peter C Taylor, Ronald F van Vollenhoven, Myron Chu, Stephen Mallett, Hayley Perry, Regina Kurrasch
Published 2016-01-01

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

by Damon Bass, Regina Kurrasch, Yoshiya Tanaka, Sang-Cheol Bae, Beulah Ji, David A Roth, Jenny Lowe, Myron Chu, Paula Curtis, Kathleen DeRose, Paige Meizlik
Published 2021-08-01